Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Source: SeekingAlpha
2026-03-27 14:56:28 ET
Investment Overview
Autolus Therapeutics plc ( AUTL ), the London, United Kingdom and Gaithersburg, Maryland headquartered, commercial stage biotech company, marketer and seller of Aucatzyl (obecabtagene autoleucel), a cell therapy indicated for adults with relapsed or refractory B-cell acute lymphoblastic leukemia, announced its Q4 and full-year 2025 earnings and business updates earlier today. At the time of writing, the stock is down ~5% for the day, trading at a value of $1.23, and Autolus' market cap valuation stands at ~$343m....
Read the full article on Seeking Alpha
For further details see:
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
20.32% G/L:
$1.895 Last:
1,717,980 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
